The current price of VOR is $18.66 — it has decreased by 7.26% since the previous close. Data as of Nov 5, 2026.
VOR is down 6.61% over the past week, up 0.43% over the past month and down 10.76% over the past year. The price is above its 200-day moving average of $17.39.
Analysts' average 12-month price target for VOR is $33.50, which implies 79.53% upside from the current price. Individual estimates range from $27.00 to $40.00.
Of the 10 analysts covering Vor Biopharma Inc., 1 rates it a strong buy, 8 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
Vor Biopharma Inc. has a market capitalization of $1.01B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Vor Biopharma Inc. posted a loss of $1.45 per share against an estimate of -$1.08, missing expectations by 34.73%. Upcoming reports are listed in the earnings calendar.
Vor Biopharma Inc. has not paid any dividends over the past year.
Companies most comparable to Vor Biopharma Inc. include CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Sana Biotechnology, Inc., Editas Medicine, Inc. and Autolus Therapeutics plc.
In the latest trading session VOR moved between $18.33 and $20.08, a range of 9.38% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Vor Biopharma Inc. shows a sell rating today and a sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Vor Biopharma Inc. is sell. Technical ratings are indicators, not investment advice.
Over the past 52 weeks VOR has traded between $6.50 and $26.00. The current price is 28.23% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.